Diag2Tec – Preclinical CRO especially in Multiple Myeloma
Home
Our Expertise
Team and History
Multiple Myeloma
Hematological Cancer Cell Lines & Primary Cells
In Vitro Model of Human Plasma Cell Differentiation
Flow Cytometry
Bioinformatic Approaches
Preclinical Services
in vitro Drug Testing
Antibody-Dependent Cellular Cytotoxicity (ADCC)
Prognosis and Predictive Biomarkers
R&D
Our ChimioFX Platform
Network
They Trusted Us
Investors
Prospects and Partners
Press & News
List of Publications and Patents
Our News
Contact
Contact us
Opportunities
Our News
Home
→
Our News
The publication’s team in the front cover of Theranostics journal
February 5, 2019
/
News
Diag2Tec s’attaque au myélome multiple
November 14, 2018
/
News
Diag2Tec présente son pitch aux investisseurs lors du salon Occitanie Invest
November 10, 2018
/
News
BioPharlAnalyses
May 28, 2018
/
News
Montpellier’s BIC
February 2, 2018
/
News
2017 Annual Congress of American Society of Hematology
December 9, 2017
/
News
Midi Libre Newspaper
June 28, 2017
/
News
Diag2Tec lauréat du concours i-Lab
July 28, 2016
/
News
i-Lab 2016 : Catégorie Création-développement
July 25, 2016
/
News
Diag2Tec visit in Florida
May 23, 2016
/
News
Interview of Jerome Moreaux, Diag2Tec’s CSO
November 4, 2015
/
News
Diag2Tec soutenue par Crealia
June 18, 2015
/
News
Jérôme Moreaux Lauréat Chercheur D’avenir 2013
February 5, 2013
/
News
Diag2Tec’s Headquarters
Diag2Tec
Cap Omega, Rond-Point Benjamin Franklin
CS 39521
34960 Montpellier, France
Email: contact@diag2tec.com
BROCHURES
Services brochure
VIDEO
Interview of Jerome Moreaux, Diag2Tec's CSO
